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Background. The World Health Organization (WHO) recommended the use of high titre measles vaccine in 1989. Subse- 
quent long term follow-up of several trials yielded results suggesting higher mortality among children inoculated with 
medium and high titre vaccines compared to standard titre vaccines, although none of the individual trials found 
significant differences in mortality. 
Methods. Long term survival after standard, medium and high titre measles vaccines has been investigated in a com- 
bined analysis of all West African trials with mortality data. In trials from Guinea-Bissau, The Gambia and Senegal, chil- 
dren received medium or high titre vaccines from 4 months of age and were compared to control groups recruited at the 
same time later receiving standard titre vaccine from 9 months of age. All children were followed up to at least 3 years 
old. 
Results. Combining trials of high titre vaccines showed higher mortality among the high titre group compared to the 
standard group: mortality ratio (MR) = 1.33 (95% CI : 1.02-1.73). Mortality among recipients of medium titre vaccines was 
not different from that in the standard vaccine group, MR = 1.11 (95% CI : 0.54-2.27). In a combined analysis by sex, 
the adjusted mortality ratios comparing high titre vaccine with standard vaccine were 1.86 (95% CI : 1.28-2.70) for 
females and 0.91 (95% CI : 0.61-1.35) for males. The trials were not designed to study long term mortality. Adjustments 
for several possible sources of bias did not alter the results. 
Conclusions. The combined analysis showed a decreased survival related to high titre measles vaccine compared with 
standard titre vaccines, though solely among females. As a result of these studies from West Africa and a study from 
Haiti, WHO has recommended that high titre measles vaccine no longer be used. 
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Measles is recognized as an important cause of both cumulative incidences of up to 15% by one year of age 
acute and delayed mortality in areas with high incidence have been reported.' The use of vaccines of increased 
of measles infection among infants and very young titre was proposed in the early 1980s as a strategy 
children. Although the standard Schwarz vaccine to induce protective immunity in the presence of mater- 
administered from 9 months of age has been successful nal antibodies, and thereby to minimize the period of 
in reducing both morbidity and mortality, a consider- susceptibility between loss of maternal antibody and 
able number of infants contract measles within their immunization.'-6 Several studies evaluating Edmonston- 
first 9 months, especially in African countries, where Zagreb (EZ) medium or high titre measles vaccine in 
infants as young as 4-6 months showed good sero- e - -  - 
conversion rates,'-6 and in 1989 the Global Advisory 
Group of the Expanded Programme on Immunization 
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'. (EPI) Of the World Health Organization (WHO) recom- 
measles in young infants is a major health problem? 
AS measles mortality is high in West Africa, control- 
led trials of medium and high titre measles vaccines 
were undertaken in Guinea-Bis~au,8*~ The Gambia"' 
mended that high titre EZ vaccine be used in areas where 
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and starting i n  1985. These trials contri- 
buted to the decision to recommend high titre vaccines. 
However, subsequent long term follow-up of the trial 
populations yielded results suggesting higher mortality 
among children inoculated with medium and high titre 
vaccines compared to those who had received standard 
titre vaccines. Reports from the studies in Guinea- 
Bissau and The Gambia were submitted to EPI in 
January 1990. In February 1991 an EPI advisory com- 
mittee mei to evaluate the unexpected findings. The 
advisory committee recommended that the use of 
high titre EZ vaccine should be continued, but noted 
that long term follow-up in future studies of measles 
vaccines was essential." After longer follow-up i n  the 
West African studies and with further data from a trial 
in comparing high and medium titre measles 
vaccines, the results from these studies were presented 
at a consultation in Atlanta in June 1992 which led the 
EPI to withdraw its recommendation for the use of high 
titre measles vaccine.I6 
This paper presents an updated combined analysis of 
data relating to long term mortality i n  medium and high 
titre measles vaccine trials in West Africa. The present 
analysis includes an additional ,-year follow-up of 
the trials in Guinea-Bissau. Though one preliminary 
analysis reported significant increased mortality." none 
of the individual trials have found significant differ- 
ences in mortality. Using data from all these studies, we 
have tried to assess whether the results are sufficiently 
consistent to warrant a firm conclusion on the value of 
these vaccines. Combining the studies has also allowed 
us to provide more accurate estimates of the sex- 
specific effects of these vaccines. The combined results 
indicate an excess mortality among high titre girl recip- 
ients compared to girls who received a standard titre 
vaccine. The results of a combined analysis comparing 
high and medium titre measles vaccine to standard titre 
vaccine have not been published previously. 
TRIALS AND METHODS 
In this report we define standard titre as 3-4 loglo PFU, 
mcdium titre as 4-5 log,, PFU and high titre as log,,, 
PFU 2 5. The WHO/EPI defined high titre vaccines as 
>5.0 log,, PFU in 1989, but revised the criterion to 
4.7 log,, PFU in 1991.;,'The abbreviations EZS, EZM, 
EZH, SWS, SWM, SWH refer to standard, medium and 
high titre Edmonston-Zage,P or Schwarz vaccines, 
respectively. $ $  
Trials 
BoriifLn, Girinea-Bissau. The two trials in Guinea- 
Bissau were Earried out in Bandim. a semi-urban part o f  
the capital city, Bissau. The first trial was a randomized 
comparison of EZM with sws Children 
born between 1 August 1984 and 31 September 1985 
received either EZM vaccine lot 529 at 4.6 logl, PFU or 
an inactivated polio vaccine (IPV) at 4 months of age, 
or SoOn thereafter. At 9 months of age, or soon there- 
after, the EZM group received IPV, While the Standard 
group received SWS. 
The second trial was carried Out using the same 
design among children being born during the period 
1 May 19S6 to 30 April 19S7.9 The first one-third ofthe 
EZ group received the same lot of EZM vaccine as in 
the first trial, but the latter two-thirds received an EZH 
vaccine, lot 81/3 at 5.2 log,, PFU. Whereas previous 
studies followed the children only to June 1990,9*'* the 
present assessment is based on a follow-up survey of all 
children carried out i n  May-August 1992 
Sukiitri, The Gmihin. Two trials were conducted in the 
Sukuta village area. 16 km from the capital Banjul.**' 
The first trial recruited children born 2-6 January 1986. 
They were randomized to receive either EZM, lot 529 
at 4.6 log,,, PFU, SWIM at 4.6 log,,, PFU. or no measles 
vaccination at age 4 months. At 9 months, the unvac- 
cinated group received SWS in addition to their yellow 
fever vaccination. Mortality data were collected at 
follow-up in January 1989 when children had reached 
3 years of age. Since there were no deaths among reci- 
pients of medium titre vaccines and only one death 
among recipients of SWS, the mortality ratio between 
vaccination groups cannot be estimated using data from 
the first Gambia trial. 
The second trial in  Sukuta consisted of children born 
April 1989-January 1990. The trial had four arms. The 
first three arms received EZH, lot 81/3 at >5 log,, 
PFU, and the fourth arm received IPV at 5 months of 
age. At 9 months of age children of the first arm 
received IPV. the second arm EZH again, and the third 
and fourth arms received EZS vaccine. lot 122/6 at <4 
I o q O  PFU. This trial contributes comparative data for 
the age interval of 5-9 months (between first and 
second vaccination) comparing the IPV group with the 
three EZH groups. Only the first and last of the four 
arms in the second Gambia trial were not revaccinated 
with measles vaccine and could be included in the 
combined analysis of high titre compared with standard 
titre vaccine. 
Nicikhnr, Seriegal. This trial was carried out in a rural 
area of Senegal and included all children born 1 Feb- 
ruary 1987-3 I January 1969.10-'3 The children were 
invited to attend vaccination sessions at 5 and 10 months 
of age. Initially. the study had three arms of the same 
!: 
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TABLE I Sirtiiinnry of stirdies evnlrtntitig iiiediriiir uird Iiigh titre tirerisles iii West Africn 
Country Location Name Birth cohorts EZ vaccines Vaccines Age at Children Deaths Child-ycars Follow-up 
titre (lot) compared vaccination (mediiin age) 
(months) 
- 
Guinea- Bandim Bandim I 1 August 1984- 4.6 (529) EZM 4 234 24 888.3 May-June 1992 
Bissau 31 September 1985 SWS 9 236 30 902.0 (87 months) 
Bandini 2 1 May 1986- 4.6 (529) EZM 4 77 18 225.2 May-June 1992 
30 April 1987 5.2 (8113) EZH 4 124 23 319.2 (67 months) 
sws 9 183 28 568.6 
Senegal Niakhar Niakhar I February 1987- 5.4 (8113) EZH 5 624 87 1886.6 February 1992 
1-24 3 I January I989 SWH 5 321 47 1092.4 (48 months) 
sws IO 634 67 1939.3 
The Sukuta Gambia 1 2 January 1985- 4.6 (529) EZM 4 119 O 375.5 January 1989 
Gambia 6 January 1986 SWM 4 43 o 135.7 (42 months) 
sws 9 119 I 324.5 
Gambia 2 April 1989- 5.0 (81) EZH-IPV 5.9 90 3 133.6 February 1992 
135.2 (30 months) 89 o January 1990 4.0 (12216) EZH-EZH 5.9 
EZH-EZS 5,9 91 3 133.8 
IPV-EZS 5.9 89 1 119.0 
size. At 5 months, the children received diphtheria- 
tetanus-pertussis-polio quadrivalent vaccine (DTP- 
IPV) and were given either an EZH vaccine, lot 8 1/3 at 
5.5 log,, PFU, an SWH vaccine, lot O980 at 5.1 log,, 
PFU, or a placebo in the standard group. At 10 months, 
all children received yellow fever and DTP-IPV 
vaccine, and the initial placebo group received an SWS 
vaccine of 3.7 log,, PFU as well. Seroconversion rates 
after SWH were found to be lower than after EZH, 
and thus it was decided to discontinue the SWH 
vaccinations in late 1988. Children born from 1 June 
1988 were randomized to either the EZH or SWS trial 
Child mortality in this trial is based on a 
census and a follow-up survey carried out in February 
1992.13 
After the trial was conducted, EZH was used as the 
routine measles vaccine in the study area, and children 
born from 1 March 1989 were administered EZH at 
5-7 months of age. Following interruption of the use 
of EZH, children born from 1 May 1990 received SWS 
at 9 months of age. A follow-up of mortality among all 
these children was performed in May 1992. 
Other studies. Studies of seroconversion after high titre 
measles vaccine have also been ,yndertaken in Togo,3 
Ivory Coast, Zaire, Sudan; Haiti 15v‘6 Peru,’g M e ~ i c o , ~  
Thailand, New Guinea,:tThe Philippines and USA, but 
most study designs did not allow for adequate follow- 
up of childhood mortality dr’r&ults were not available 
for inclusion in the combined analysis. A study com- 
paring medium and high titre measles vaccines was 
conducted in Haiti,I6 but as medium and high titre 
B 
vaccines were compared this trial cannot add to our 
comparison between standard and higher titre vaccines. 
The studies included in the present analysis are from 
neighbouring countries i n  West Africa with several 
similar design features, which provide some justifica- 
tion for assuming common vaccine effects in  this com- 
bined analysis. 
A summary of locations, vaccine types and designs 
of the West African medium and high titre measles vac- 
cine studies described in this paper is given in Table 1. 
Methods and results of these studies are described in 
more detail e l s e ~ h e r e . ’ . ~ * ~ * * - ~ ~ * ’ ~  
Methods 
Because the trials in Guinea-Bissau, Senegal and partly 
The Gambia had similar experimental designs with 
exact dates of recruitment, follow-up and death 
recorded, an identical analysis using a proportional 
hazards model for survival data” could be performed 
within each trial and the results from all trials could 
be combined. Children were included from the time of 
their first vaccination, regardless of whether they had 
received a measles vaccine or a placebo, and followed 
until death, migration or follow-up. The previous stud- 
ies of the two trials in Guinea-Bissau had monitored 
child survival after migration by interviewing relatives 
and neighbours. Here, we have stopped follow-up at 
t: migrqtion in all trials. Mortality rates decline rapidly 
’ with age during the first 3 years of life, and the variation 
in age at first vaccination was considerable between 
studies. For this reason, age has been used as the 
underlying time scale in a proportional hazards model. 
668 INTERNATIONAL JOURNAL OF EPlDEMlOLOCY 
Children have thus been compared from age at first 
vaccination unt i l  age at death or censoring. Potential 
confounders, e.g. sex, seasonality, measles infection, 
separation from mother and presence at second vaccina- 
tion session, were controlled using a multivariable sur- 
vival analysis. Effects are given as mortality rate ratios 
for recipients of high or medium titre vaccines against 
the standard group assigned to receive the standard titre 
Schwarz vaccine (SWS) after 9 months of age. 
A combined mortality ratio (MR) was derived by 
pooling log mortality ratios of each trial i n  a random 
effects model which incorporates both sampling varia- 
tion within each trial and variation between trials.” 
Because the two high titre vaccine groups had a com- 
mon standard group in the Niakhar trial, the vaccine 
effect estimates are not independent and can there- 
fore not be included separately in a combined analysis. 
The common mortality ratio in the Niakhar study 
was derived using a stratified proportional hazards 
analysis, such that recipients of SWH have been 
compared only with the standard group born in the 
same 16-month period, and recipients of EZH with 
all the standard group born during the entire 2-year 
period. In  the second Bandim trial, recipients of 
medium titre vaccine have been compared to children 
from the standard group who were immunized at the 
same time, i.e. the first one-third of the group, while 
recipients of high titre vaccine have been compared to 
the last two-thirds of the standard vaccine group. 
Mortality ratios are calculated for medium and high 
titre vaccines separately. In the Gambia trials the 
number of deaths was small and only crude analyses 
could be performed. 
The main survival analyses are based on deaths 
reported for residents in the study areas. Thus, follow- 
up is discontinued at emigration, but the analysis allows 
for possible re-entry into the study area. Analyses were 
also performed censoring at the time of measles 
infection, if any, and for the subgroup of children who 
received their first injection before the age of 9 months, 
the earliest recommended age for the Schwarz standard 
vaccine. Crude analyses are controlled for age, while 
the adjusted analyses control for age, sex, season (rainy 
or dry) and measles infection. The Niakhar data are 
adjusted also for presence at the IO-months medical 
examination and separation from mother. Mortality 
ratios are calculated from tw?ca,ges: (i) the complete 
trial period, which is fi;om fir,$ vaccination to follow- 
up. and (i¡) from thq second baccination for the sub- 
group receiving both injections. In addition, mortality f,‘ 
has been compared for the pkiiod from first to second 
vaccination, or to 10 months of age, whichever occurs 
first. 
TAßLE 2 Relcitive niormlily dirring tlie itirerynl betwee/i/irsr mid 
secoiid vucciticitiotis cittiorig recipients of ntediiirti or high titre 
vricciries, conipored lo cotitrols WIIO hacl trot pel received 
sr(irrifkird titre vrircitie. f o r  each of {lie &’est Africciti trials. 
septircirel~ mid cot~il~itied 
Individual trials Crude 95% confidence 
ratio 
mortality interval 
Medium titre 
B:indim 1 E F  0.56 (O. 13-2.35) 
(0.36-6.96 j B:indim 2 E2 1.80 
Bandim 2 EZ 1.17 (0.313.35) 
High titre 
Gambia 2 E2 0.33 (0.02-520) 
Niakhar SWb 2.23 (0.76-6.53 j 
Niakhar EZ 0.52 (O. 18- I .52) 
Combined results 
Medium titre trials I .O3 (0.33-3.22) 
High titre triills 0.96 (0.49-1.87 j 
All trials I .o0 (0.58-1.74) 
Ednionston-Zagreb. 
Schwarz. 
RESULTS 
The numbers or” children under study and the numbers 
of deaths in  each vaccine group for the different trials 
are presented in Table 1. The randomized trials with 
detail mortality data from Guinea-Bissau, Senegal and 
The Gambia involved 3073 children, with a total of 339 
deaths in 11 129 child-years of follow-up. 
Mortality Between First and Second Vacciiiatioti 
Table 2 shows mortality ratios for the period between 
the first vaccination and either the second vaccination 
or 10 months, whichever occurs first i.e. the time before 
the control group had received measles vaccine. Al- 
though mortality ratios varied widely between studies, 
combined mortality ratios were similar for medium and 
high titre recipients compared to the standard group; 
medium titre: MR = 1.03 (95% CI : 0.33-3.22); high 
titre: MR = 0.96 (95% CI : 0.49-1.87). Note that because 
of the small numbers of deaths occurring in the interval 
between first and second vaccinations confidence inter- 
vals are wide. 
Overnil iLJortaiity 
The estimated mortality ratios comparing high or medi- 
um titre vaccines against placebolSchwarz standard are 
listed, in Table 3. Both crude and adjusted mortality 
ratios are given. Considering individual trials separ- 
ately, no differences in mortality between medium 
or high titre and standard vaccine were, significant at 
'Il f irs1 llr1cl 
Iiigli titre 
r receit-ed 
cuti ~rkils. 
:on fidence 
tterval 
13-2.35) 
16-6.96) 
514.35) ' 
12-5.20) 
:8-1.52) 
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TABLE 3 Rcltirive itrorrctliry oi~ioi ig  recipietirs of nrecliioii or Iii.y/i 
tirre vciccities, coiti1"wl IO recipietifs of sfmidcird litre ~nccbies. 
doriiig from the first or secoiid vcicciitrrrinii. Criide ritid ncljiisrerl 
mortdity mrios (nrrtl952 cotifidetice i t i fovr i l )  are giveti for ecich 
of rlie siridies separcirely nnd coiirbitred 
~ 
Individual trials From first From second 
vaccination vaccination 
Medium titre 
Bandim 1 EZM" crude 0.81 (0.47-1.38) 
adjusted 0.87 (0.50-1.50) 
Bandim 2 EZM crude 1.69 (0.78-3.67) 
adjusted 1.68 (0.77-3.64) 
High titre 
Bandim 2 EZHb crude 1.35 (0.73-2.51) 
adjusted 1.50 (0.80-2.79) 
Gambia 2 crude 2.89 (0.30-27.82) 
Niakhar EZH crude 1.33 (0.96-1.83) 
adjusted 1.33 (0.96-1.83) 
Niakhar SWH' crude 1.43 (0.93-2.21) 
adjusted 1.42 (0.93-2.19) 
Combined results 
Medium titre crude 1.1 I (0.54-2.27) 
adjusted 1.14 (0.96-2.14) 
High titre crude 1.33 (1.02-1.73) 
adjusted 1.34 (1.02-1.75) 
~ 
0.94 (0.51-1.75) 
I .O6 (0.56-2.00) 
1.72 (0.63-4.74) 
1.70 (0.62469) 
1.24 (0.61-2.55) 
I .38 (0.67-2.86) 
t 
1.56 (1.09-2.55) 
1.57 (1.09-2.86) 
1.43 10.86-2.40) 
1.43 (0.86-2.39) 
1.1 1 (0.65-1.89) 
1.21 10.71-2.07) 
1.41 (1.04-1.92) 
I .-II ( I .06- I .96) 
Edmonston-Zagreb medium titre. 
Edmonston-Zagreb high titre. 
Schwarz high titre. 
? No deaths were recorded in the last arm of the second Gambia trial 
after the second vaccination so a mortality ratio could not be 
calculated. 
the conventional 5% level for the crude age-adjusted 
comparisons. 
Table 3 also shows results of the combined analyses. 
Combining the results of the different trials, the recip- 
ients of medium titre vaccines exhibited no significant 
difference in mortality, M R =  1.11 (95% CI : 0.54- 
2.27), whereas recipients of high titre vaccines had 
significantly higher mortality than the standard group, 
MR = 1.33 (95% CI : 1.02-1.73). If the comparison is 
limited to trials using Schwarz as standard titre vaccine, 
i.e. excluding the Gambia 2 trial, MR = 1.31 (95% 
CI : 1.01-1.71). Combining both medium and high titre 
vaccine trials, the MR was 1,22 (955%-CI : 0.88-1.71) 
compared with the standard' grou& The results of the 
adjusted analyses were drtually identical. The crude 
results are shown graphically in Figure 1, in which the 
mortality ratios and 95% c o d k c h e  intervals of each 
study are portrayed together with the joint estimates. 
Homogeneity of the vaccine effects could be assumed 
within the high titre trials (test for homogeneity: 
x'= 0.68, 1 d.f., P = 0.41) and within the medium titre 
trials (test for homogeneity: x' = 2.36, 1 d.f., P = 0.07), 
although the latter difference approaches statistical 
significance. Since few trials are combined in both the 
medium and high titre groups, the power of this test to 
detect any differences is low. 
Considering siirvival from the second vaccination, 
whkn children i n  the standard group had also received 
measles vaccine, recipients of high titre vaccine had an 
MR of 1.4 1 (95% CI : 1.04-1.92), whereas it was 1.1 1 
(95% CI : 0.65-1 3 9 )  for recipients of medium titre vac- 
cines. Again results were very similar in  the adjusted 
analyses. Results of the individual trials and the com- 
bined results on survival from the second vaccination 
are shown in Table 3. 
The estimated mortality ratios are unaltered if 
censoring is performed at onset of measles illness. 
Restricting the analysis to children who received their 
first injection before 9 months of age, the recommended 
age of standard Schwarz, the combined adjusted mort- 
ality ratio is MR = 1.23 (95% CI : 0.97-1.5:). which is 
similar to the combined estimate of all children in the 
medium and high titre trials. 
Mortality by Sex 
No interactions have been identified in t h e  individual 
trials apart from an interaction between vaccine type 
and sex. Excess mortality among female EZH recipients 
was noted initially in the Bissau trialsg and reported to 
WHO." Interactions of vaccine effect with sex adjusted 
for other factors are summarized in Table 4. The diverg- 
ence between medium or high titre vaccine recipients 
and the standard group was greater in females than 
males in all but the first Bandim trial. In the medium 
titre trials combined, no interaction between sex and 
vaccine type was found, x' = 3.132, d.f. = 2, P = 0.209. 
The high titre trials display a significant vaccine-sex 
interaction, even after controlling for other factors, 
xz = 8.508, d.f. = 2, P = 0.014. Sex-specific estimates 
are shown in Table 4. In  a combined analysis, the 
adjusted sex-specific mortality ratio comprising female 
high titre recipients with female recipients of SWS is 
1.86 (95% CI : 1.28-2.70) whereas there was no differ- 
ence for male recipients of high titre vaccine compared 
to the standard group, MR = 0.91 (95% CI : 0.61-1.35). 
Mortality by Age 
Since interaction between age and vaccine type was 
t: suggested. in the Niakhar trial," this interaction was 
examined in the combined analysis. It was not found 
to  be significant (x' = 6.319, d.f. = 3, P = 0.097). 
However, there was some evidence for a lag in the 
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Crude Mortality Ratio & Confidence Intervals Approximate Weight 
Medium or High Titre Bener Medium or High Titre Worse 
Bandim 1 EZM 
Bandim 2 EZM 
Medium Titre Trb., 
Bandim 2 EZH 
Gambia 2 EZH 
Niakhar EZH+SWH 
High Titre Trials 
-"f 
1.1 1 (0.54-2.27) = 
V I 
1.33 (1 .oz-1.73) 
0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 
18 
5 
13 
1 
59 
Crude Mortality Ratio of Medium and High versus Standard Titre 
FIGURE 1 Combined crude analysis of West African medium and high titre vaccine trials fromfirst vaccination. Solid 
sqirares represent the rate ratios of mortality in the individual trials and empty squares represent the combined 
estimates. The sizes of the sqrrares are proportional to the amount of 'information' contribirted by that study, also given 
by the approximate weights. The 95% confidence intervals are denoted by lines 
EZM Edmonston-Zagreb medium titre 
EZH Edmonston-Zagreb high titre 
SWH Schwarz high titre 
TABLE 4 Mortality ratios by se.r for  recipients of medirrm and high titre vaccines compared to recipients of the standard vaccine of the 
same gender. Adjusted estimares (95% conJdence interval) and tests for interaction controlling f o r  age, season, measles infection and. for 
the Ninkhar triul. presence at I O  months 
Males Females Test for interaction 
Individual trials 
Medium titre 
Bandim 1 EZM' 1.30 (0.62-2.72) 
Bandim 2 EZM (' ,435 (0.4253.72) 
0.52 (0.22-1.23) 
2.26 (0.72-7.1 1) 
0.50 (0.15-1.71) 2.31 (1.09488) 
High titre ' '6 
Combined results * ,  . 
Medium titre 1.28 (0.70-2.37) 0.88 (0.45-1.74) 
High titre 0.9 1 (0.6 1-1.35) 1.86 (1.28-2.70) 
Bandim 2 EZHb : 
0.97 (0.64-1.47) f '  1.73 (1.13-2.66) . .  Niakhar EZH+SWHc 
, ' .L . 1? 
a EZX1 Edmonston-Zagreb medium titre. 
EZH Edmonston-Zagreb high titre. 
SWH Schwan: high titre. 
of the 
i d ,  for 
O. 108 
0.459 
0.028 
0.055 
0.209 
0.014 
. .. 
.-. 
CHILD MORTALITY FpLLOWlNG STANDARD. MEDIUh.1 OR HIGH TITRE MEASLES IMMUNIZATION IN WEST AFRICA 67 I 
differential mortality between higher titre and Schwarz 
standard titre recipients. In their first year of life, no 
excess mortality occurred: crude MR = 1 .O0 (95% CI : 
0.66-1.52). From one to 2 years of age. the mortality 
ratio was 1.06 (95% CI : 0.7 1-1.58) increasing to MR = 
2:12 (95% CI : 1.28-3.51) i n  the age interval from 2 to 
3 years and after 3 years of age falling to MR = 1.14 
(95% CI : 0.66-1.95). These estimates reflect solely 
differences in female mortality. 
DISCUSSION 
The West African studies discussed here were designed 
to measure immunogenicity and clinical protection as 
the main outcomes for comparing high or medium titre 
measles vaccines given at an earlier age with standard 
titre Schwarz given at 9-10 months of age. Although 
the trial protocols mention safety, sample size consid- 
erations did not include the question of adverse mort- 
ality effects of the introduction of a new vaccine policy. 
Since the trials in  Guinea-Bissau, Senegal and The 
Gambia were part of the demographic surveillance 
systems monitoring child morbidity, immunizations, 
mortality and movements, it was possible to carry out 
detailed survival analysis of the trial populations. 
Because the trials were not carried out or designed for 
an analysis of long term mortality, but for evaluating 
measles morbidity, significance of test results at a 5% 
level should not be interpreted too literally, as these 
trials were addressing mortality as the secondary 
outcome, not the primary outcome. 
The excess mortality discussed in this paper was not 
statistically significant in any of the individual trials 
when evaluated from the first vaccination and was only 
statistically significant in one comparison after the sec- 
ond vaccination (EZH versus SWS, Table 3). Combina- 
tion of all the West African trials of medium and high 
titre vaccines resulted in a mortality ratio of 1.21 (95% 
CI : 0.89-1.63). The excess mortality reached convent- 
ional levels of statistical significance only when analy- 
ses were restricted to combined analyses of all high titre 
vaccine recipients, compared with standard titre 
recipients, M R =  1.33 (95% CI : 1.02-1.73). All analy- 
ses, crude and adjusted, as well as those including 
follow-up after migration and excluding time after 
measles infection, showed similar mortality ratio point 
estimates. The consistency in the est!-mates of reduced 
survival in connection with high titte vaccines is evid- 
ence that the result is robust with’trespect to possible 
confounders. Because the observed mortality ratios of 
the high titre trials are close, .$e ifandom effects model 
delivers the same result as a fixed effect model. It should 
be noted that we have used recipients of both standard 
titre EZ and standard titre Schwarz as the control group 
since this is currently the recommended dose of measles 
vaccine. Even if the recipients of EZS were excluded 
from the standard group, we obtained similar estimates 
of the difference between high and standard titre. 
In addition to the overall difference i n  mortality, 
there are particular aspects of the combined analysis 
that may be indicative. First, no difference was observed 
i n  mortality between medium or high titre recipients 
and children who had not yet received measles vac- 
cine (Table 2). The entire difference in mortality was 
found after the children in the control group had re- 
ceived standard Schwarz vaccine, MR = 1.41 (95% CI : 
Second, the excess mortality in the high titre group 
was restricted to females. The mortality was signifi- 
cantly greater among high titre female vaccinees com- 
pared with standard titre female vaccinees, but there 
was no difference between mortality in medium or high 
titre male recipients and SWS males. The interaction 
between vaccine type and sex was the only significant 
interaction found in the combined analysis. Given that 
this sex effect was unexpected, i t  should be viewed with 
caution. On the other hand. it gains credence by its con- 
sistency, having been observed in three trials (Guinea- 
Bissau,’ Senegal” and Haiti’’) as well as in  post-trial 
data from Senegal (authors’ unpublished data). 
What are the possible explanations for these unex- 
pected findings? All the trials compared different 
vaccines at different ages. Analysis of the Bandim 
trials, where there was a large variation in the age at 
vaccination, found no evidence that age at  measles 
vaccination was responsible for the effect. A difference 
in vaccine response could influence vaccine-inducing 
protection, but differences in protection were not 
found**” and the known cases of measles cannot 
explain the excess deaths among recipients of high titre 
vaccine. A specific batch of high titre measles vaccine 
does not appear to be responsible for the excess deaths, 
as both high titre EZ and high titre Schwarz vaccines 
showed similar associations with higher mortality. 
Since there was no overall evidence for a difference in 
mortality in the medium titre trials, a simple explana- 
tion for the increased mortality in the high titre trials is 
that the high dose of vaccine was responsible for the 
differences. However, this inference is weak, as only a 
small number of children were included in the medium 
titre studies.” 
The results from Guinea-Bissau, Senegal and Haiti, 
all with. hi.gh background child mortality, showed an 
association between high dose measles vaccines and 
decreased survival, especially among females, while 
studies from The Gambia’ and Me~ico , ’~  where there 
1.04-1.92). 
‘ I  
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was low background infant mortality, displayed no 
difference in mortality. This suggests that the medium 
and high titre vaccines do not cause excess mortality by 
themselves, and have been interpreted as evidence that 
any high dose vaccine attributable effect on mortality is 
multiplicative rather than a d d i t i ~ e . ' ~  It has also been 
suggested that the impact of the vaccine may corres- 
pond to the delayed excess mortality reported after 
measles infection.I6 However, even in areas with high 
mortality, medium and high titre vaccines were not 
associated with increased mortality between 5 and 10 
months of age, when the standard group were still not 
immunized against measles. Since the difference is only 
found after the standard group have received SWS and 
in areas with high background mortality, the observed 
mortality differences may be attributable to beneficial 
effects of SWS vaccines, particularly for girls, which 
are not reproduced by the high titre vaccines.'4 In this 
context it is notable that studies in Bissau," Senegalz4 
and Haiti," have shown greater reductions in all cause 
mortality among recipients of standard measles vac- 
cines, than could be explained by the prevention of 
acute measles deaths alone. In  conclusion. there is no 
conclusive evidence that high titre vaccines are delet- 
erious and i t  remains possible that they are just less 
beneficial than standard titre vaccines. 
The findings from the these studies in West Africa 
and Haiti led the WHO/EPI to recommend that the use 
of high titre measles vaccine be ~ t o p p e d . ' ~  I n  addition, 
the EPI now recommends that post licensure field 
studies of new measles vaccines be designed so that late 
mortality can be evaluated. Given the evidence that the 
excess mortality was restricted to females, community 
studies of measles-related morbidity and mortality 
should be analysed for differential effect by sex. The 
interaction between sex and vaccine type requires 
further study. Despite the disappointment associated 
with the discontinuation of what had been considered a 
promising tool for measles control, the unexpected 
results from these studies should encourage further 
research towards more effective vaccination strategies 
against measles. 
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